Kala Bio (LTS:0JQ2) Additional Paid-In Capital : $647.87 Mil(As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Kala Bio Additional Paid-In Capital?

Kala Bio's quarterly additional paid-in capital increased from Sep. 2023 ($632.00 Mil) to Dec. 2023 ($636.91 Mil) and increased from Dec. 2023 ($636.91 Mil) to Mar. 2024 ($647.87 Mil).

Kala Bio's annual additional paid-in capital increased from Dec. 2021 ($559.19 Mil) to Dec. 2022 ($606.18 Mil) and increased from Dec. 2022 ($606.18 Mil) to Dec. 2023 ($636.91 Mil).

Kala Bio Additional Paid-In Capital Historical Data

The historical data trend for Kala Bio's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kala Bio Additional Paid-In Capital Chart

Kala Bio Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

325.11

499.72

559.19

606.18

636.91

Kala Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															625.12	629.56	632.00	636.91	647.87

Kala Bio Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Kala Bio Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Kala Bio's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Kala Bio (LTS:0JQ2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kala Bio Inc (LTS:0JQ2) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

KALA:USA 27F0:Germany

Address

1167 Massachusetts Avenue, Arlington, MA, USA, 02476

Website

https://www.kalarx.com

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing innovative therapies for rare and severe eye diseases. KALA's lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Kala Bio (LTS:0JQ2) Headlines

No Headlines